EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2026
Early outcomes of transcatheter vacuum-assisted mass extraction in the left heart and the aortic arch.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fang Jonathan X, O'Neill Brian P, Frisoli Tiberio M, Eng Marvin H, Gonzalez Pedro Engel, Shimamura Junichi, Ahmad Hasan A, Haidry Syed Abbas, Giustino Gennaro, Jabri Ahmad, Ibrahim Reda, von Bardeleben Ralph Stephan, Gregerson Samuel, Giacaman Arturo, Chiang Michael, So Kent Chak-Yu, Lok Lai Leo Kar, Lee James C, Zweig Bryan, Fram Georgi K, Wang Dee Dee, O'Neill William W, Villablanca Pedro A
Аннотация
BACKGROUND: Transcatheter vacuum-assisted mass extraction (TVME) in the systemic circulation is increasingly being reported. However, its feasibility, effectiveness, and safety remain poorly defined.
AIMS: We sought to investigate the feasibility, effectiveness and safety of TVME in the left heart and aortic arch.
METHODS: Consecutive patients from 6 centres in the United States and Canada were included. Feasibility was defined as technically successful mass extraction without unplanned cardiac surgery or intraprocedural mortality. The effectiveness endpoint was feasibility with successful debulking of ≥70% mass volume. The primary safety endpoint was the 30-day composite of procedure-attributable mortality, major cardiac structural complications, major vascular complications, Type 3-4 bleeding, acute coronary syndrome (ACS), and stroke, all according to Valve Academic Research Consortium (VARC)-3 definitions. Intraprocedural events were also reported.
RESULTS: A total of 62 consecutive patients were evaluated. Feasibility was reached in 85.5% of patients and effectiveness in 77.4% of patients - except for 11.3% with suboptimal debulking, 3.2% with access-related case abortion, and 8.1% with case cancellation where no mass was found intraprocedurally. The primary safety endpoint occurred in 14.5% of patients, with a procedure-attributable mortality rate of 3.2%. VARC-3 major cardiac structural complications, major vascular complications, Type 3-4 bleeding, ACS, and stroke occurred in 3.2%, 8.1%, 3.2%, 3.2%, and 6.5% of patients, respectively. Intraprocedural events included hypoxia (6.5%), hypotension (9.7%), embolism (3.2%), air embolism (1.6%), and increased mitral regurgitation (6.5%).
CONCLUSIONS: TVME in left-sided and aortic arch masses is feasible and demonstrates reasonable effectiveness. However, the considerable rate of safety-related events highlights the need for better case selection and procedural refinement, such as optimal embolic protection.
AIMS: We sought to investigate the feasibility, effectiveness and safety of TVME in the left heart and aortic arch.
METHODS: Consecutive patients from 6 centres in the United States and Canada were included. Feasibility was defined as technically successful mass extraction without unplanned cardiac surgery or intraprocedural mortality. The effectiveness endpoint was feasibility with successful debulking of ≥70% mass volume. The primary safety endpoint was the 30-day composite of procedure-attributable mortality, major cardiac structural complications, major vascular complications, Type 3-4 bleeding, acute coronary syndrome (ACS), and stroke, all according to Valve Academic Research Consortium (VARC)-3 definitions. Intraprocedural events were also reported.
RESULTS: A total of 62 consecutive patients were evaluated. Feasibility was reached in 85.5% of patients and effectiveness in 77.4% of patients - except for 11.3% with suboptimal debulking, 3.2% with access-related case abortion, and 8.1% with case cancellation where no mass was found intraprocedurally. The primary safety endpoint occurred in 14.5% of patients, with a procedure-attributable mortality rate of 3.2%. VARC-3 major cardiac structural complications, major vascular complications, Type 3-4 bleeding, ACS, and stroke occurred in 3.2%, 8.1%, 3.2%, 3.2%, and 6.5% of patients, respectively. Intraprocedural events included hypoxia (6.5%), hypotension (9.7%), embolism (3.2%), air embolism (1.6%), and increased mitral regurgitation (6.5%).
CONCLUSIONS: TVME in left-sided and aortic arch masses is feasible and demonstrates reasonable effectiveness. However, the considerable rate of safety-related events highlights the need for better case selection and procedural refinement, such as optimal embolic protection.